Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | The next steps in utilizing radiation for oligometastatic prostate cancer

Sophia Kamran • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer 177Lu-PSMA-617

Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, describes the future role of radiation for oligometastatic disease, highlighting ongoing trials that are evaluating novel combinations and adaptive radiation strategies. Various trials are incorporating the early use of androgen receptor pathway inhibitors (ARPIs), and novel combinations such as 177Lu-PSMA-617 plus metastasis-directed therapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sophia Kamran

Advances in the diagnostic imaging of oligometastatic prostate cancer
1:07
Advances in the diagnostic imaging of oligometastatic prostate cancer
Sophia Kamran • 14 Feb 2025
Real-world use of radiotherapy in de novo oligometastatic prostate cancer
3:27
Real-world use of radiotherapy in de novo oligometastatic prostate cancer
Sophia Kamran • 14 Feb 2025
The role of radiation in managing high-risk localized prostate cancer
2:44
The role of radiation in managing high-risk localized prostate cancer
Sophia Kamran • 26 Jan 2024
How can radiotherapy make prostate cancer more immunogenic?
3:09
How can radiotherapy make prostate cancer more immunogenic?
Sophia Kamran • 26 Jan 2024

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals